All Stories

  1. Multiple 11C-acetate and 18fludeoxyglucose-avid hepatic tumours in a young woman: primary, secondary, or something else?
  2. Correction: Long-Term Survival Outcome Between Living Donor and Deceased Donor Liver Transplant for Hepatocellular Carcinoma: Intention-to-Treat and Propensity Score Matching Analyses
  3. Defining Global Benchmarks for Robotic Liver Resections
  4. Attenuation of the second peak of bimodal recurrence of HBV-related HCC after curative treatment in the antiviral era
  5. Long-term survival after extended resection combined with pericardiectomy for locally advanced intrahepatic cholangiocarcinoma: a case report
  6. Data from PEG-BCT-100 and Canavanine Synergistically Induce Apoptosis in Arginine Biosynthetic Enzyme-Deficient Pancreatic Cancer
  7. FigS1 from PEG-BCT-100 and Canavanine Synergistically Induce Apoptosis in Arginine Biosynthetic Enzyme-Deficient Pancreatic Cancer
  8. FigS2 from PEG-BCT-100 and Canavanine Synergistically Induce Apoptosis in Arginine Biosynthetic Enzyme-Deficient Pancreatic Cancer
  9. FigS3 from PEG-BCT-100 and Canavanine Synergistically Induce Apoptosis in Arginine Biosynthetic Enzyme-Deficient Pancreatic Cancer
  10. Figure 1 from PEG-BCT-100 and Canavanine Synergistically Induce Apoptosis in Arginine Biosynthetic Enzyme-Deficient Pancreatic Cancer
  11. Figure 2 from PEG-BCT-100 and Canavanine Synergistically Induce Apoptosis in Arginine Biosynthetic Enzyme-Deficient Pancreatic Cancer
  12. Figure 3 from PEG-BCT-100 and Canavanine Synergistically Induce Apoptosis in Arginine Biosynthetic Enzyme-Deficient Pancreatic Cancer
  13. Figure 4 from PEG-BCT-100 and Canavanine Synergistically Induce Apoptosis in Arginine Biosynthetic Enzyme-Deficient Pancreatic Cancer
  14. Figure 5 from PEG-BCT-100 and Canavanine Synergistically Induce Apoptosis in Arginine Biosynthetic Enzyme-Deficient Pancreatic Cancer
  15. Figure 6 from PEG-BCT-100 and Canavanine Synergistically Induce Apoptosis in Arginine Biosynthetic Enzyme-Deficient Pancreatic Cancer
  16. Proton beam therapy in the management of hepatocellular carcinoma
  17. Hepatic artery infusion chemotherapy: A resurgence
  18. PEG-BCT-100 and Canavanine Synergistically Induce Apoptosis in Arginine Biosynthetic Enzyme-Deficient Pancreatic Cancer
  19. Surgical cystogastrostomy: Is it still worthwhile?
  20. Hong Kong consensus recommendations on the management of pancreatic ductal adenocarcinoma
  21. Immunotherapy before and after liver transplantation, where are we now?
  22. The Hong Kong consensus recommendations on the diagnosis and management of pancreatic cystic lesions
  23. Enhanced recovery for liver transplantation: recommendations from the 2022 International Liver Transplantation Society consensus conference
  24. Impact of Tumour Biology on Outcomes of Radical Therapy for Hepatocellular Carcinoma Oligo-Recurrence after Liver Transplantation
  25. Anatomical limits in living donor liver transplantation
  26. The role of the graft to recipient weight ratio on enhanced recovery of the recipient after living donor liver transplantation – A systematic review of the literature and expert panel recommendations
  27. Erratum: Defining the role of laparoscopic liver resection in elderly HCC patients: a propensity score matched analysis
  28. Experience of living donor liver transplantation for hepatocellular carcinoma in the University of Hong Kong Hospital
  29. Verifying the Benefits of Radical Treatment in Posttransplant Hepatocellular Carcinoma Oligo‐recurrence: A Propensity Score Analysis
  30. Immunotherapy after liver transplantation: Where are we now?
  31. Performance of Dual-tracer PET-CT for Staging Post–Liver Transplant Hepatocellular Carcinoma Recurrence
  32. Critical appraisal of TNM versus HKU staging system for postoperative prognostic evaluation of hepatocellular carcinoma
  33. Liver transplantation: would it be the best and last chance of cure for hepatocellular carcinoma with major venous invasion?
  34. Role of C11-FDG dual-tracer PET-CT scan in metastatic screening of hepatocellular carcinoma—a cost-effectiveness analysis
  35. RSK2-inactivating mutations potentiate MAPK signaling and support cholesterol metabolism in hepatocellular carcinoma
  36. Defining the role of laparoscopic liver resection in elderly HCC patients - a propensity score matched analysis
  37. Indocyanine green fluorescence-assisted laparoscopic hepatectomy for hepatocellular carcinoma in a pre-adolescent girl: a case report
  38. Transferability of Liver Transplantation Experience to Complex Liver Resection for Locally Advanced Hepatobiliary Malignancy – Lessons Learnt From 3 Decades of Single Center Experience
  39. Initial experience with stereotactic body radiotherapy for intrahepatic hepatocellular carcinoma recurrence after liver transplantation
  40. Mammalian target of rapamycin inhibitors after post-transplant hepatocellular carcinoma recurrence: Is it too late?
  41. The Risk of Going Small
  42. HBV‐ TERT Promoter Integration Harnesses Host ELF4 Resulting in TERT Gene Transcription in Hepatocellular Carcinoma
  43. Expanding Indications for Liver Transplant: Tumor and Patient Factors
  44. Model for End‐stage Liver Disease with additional criteria to predict short‐term mortality in severe flares of chronic hepatitis B
  45. Determining the optimal timing of liver transplant for pediatric patients after Kasai portoenterostomy based on disease severity scores
  46. Impact of Graft Steatosis on Long-Term Graft Survival in Liver Transplantation
  47. Impact of small-for-size liver grafts on medium-term and long-term graft survival in living donor liver transplantation: A meta-analysis
  48. Survival analysis of breast cancer liver metastasis treated by hepatectomy: A propensity score analysis for Chinese women in Hong Kong
  49. Is the treatment outcome of hepatocellular carcinoma inferior in elderly patients?
  50. Sarcopenia in pancreatic cancer – effects on surgical outcomes and chemotherapy
  51. ALPPS Versus Portal Vein Embolization for Hepatitis-related Hepatocellular Carcinoma
  52. Prognostic value of preoperative alpha-fetoprotein (AFP) level in patients receiving curative hepatectomy- an analysis of 1,182 patients in Hong Kong
  53. Feasibility of next-generation sequencing of circulating tumor cells for predicting relapse after liver resection in metastatic colorectal cancer
  54. Donor ductal anomaly is not a contraindication to right liver lobe donation
  55. Validated model for prediction of recurrent hepatocellular carcinoma after liver transplantation in Asian population
  56. Induction of Oxidative Stress Through Inhibition of Thioredoxin Reductase 1 Is an Effective Therapeutic Approach for Hepatocellular Carcinoma
  57. Prospective Study on Sexual Dysfunction in Male Chinese Liver Transplant Recipients
  58. Liver transplantation using hepatitis B core positive grafts with antiviral monotherapy prophylaxis
  59. Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis
  60. Colorectal liver metastases: An update on multidisciplinary approach
  61. Long-Term Survival Outcome Between Living Donor and Deceased Donor Liver Transplant for Hepatocellular Carcinoma: Intention-to-Treat and Propensity Score Matching Analyses
  62. Adjuvant chemotherapy improves oncological outcomes of resectable intrahepatic cholangiocarcinoma
  63. Hepatectomy bridges to transplant—the road to cure?
  64. Pneumocystis jirovecii-related spontaneous pneumothorax, pneumomediastinum and subcutaneous emphysema in a liver transplant recipient: a case report
  65. Validated nomogram for the prediction of disease-free survival after hepatectomy for hepatocellular carcinoma within the Milan criteria: individualizing a surveillance strategy
  66. Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: A proposed management algorithm
  67. Emergency ABO-incompatible living donor liver transplant for patients with ultrahigh MELD scores
  68. A vena caval mass: challenging diagnosis with a rare complication
  69. What Can We Learn from Living Donor Evaluation? A Higher Prevalence of Metabolic Disease and Less Technical Contraindication
  70. Defining Optimal Surgical Treatment for Recurrent Hepatocellular Carcinoma: A Propensity Score Matched Analysis
  71. Minimally invasive donor hepatectomy, are we ready for prime time?
  72. Partial portal vein arterialization using right gastroepiploic artery: A novel solution for portal hypoperfusion
  73. Recurrent pyogenic cholangitis – an independent poor prognostic indicator for resectable intrahepatic cholangiocarcinoma
  74. Hepatitis B vaccination in patients receiving oral antiviral therapy without hepatitis B immune globulin after liver transplantation
  75. Risk Factors for Graft Steatosis after Liver Transplantation using Controlled Attenuation Parameter Measurements
  76. Excellent Perioperative and Long-Term Outcomes with Lower Graft-to-Recipient Weight Ratio for Living Donor Liver Transplantation
  77. Prospective Trial on Sexual Dysfunction in Male Chinese Liver Transplant Recipients
  78. Validated Nomogram for Prediction of Recurrence in HCC within Milan Criteria
  79. Anterior Approach to Major Resection for Colorectal Liver Metastasis
  80. Prevention of post-sphincterotomy bleeding by proton pump inhibitor: A randomized controlled trial
  81. Pure laparoscopic hepatectomy with augmented reality-assisted indocyanine green fluorescence versus open hepatectomy for hepatocellular carcinoma with liver cirrhosis: A propensity analysis at a single center
  82. Changing Paradigm in the Surgical Management of Hepatocellular Carcinoma With Salvage Transplantation
  83. Liver Transplantation for Hepatitis B Virus-related Hepatocellular Carcinoma in Hong Kong
  84. Survival outcomes of liver transplantation for hepatocellular carcinoma in patients with normal, high and very high preoperative alpha-fetoprotein levels
  85. Hepatocholangiocarcinoma/intrahepatic cholangiocarcinoma: are they contraindication or indication for liver transplantation? A propensity score-matched analysis
  86. Asia's first combined liver transplant and aortic valve replacement
  87. Major postoperative complications compromise oncological outcomes of patients with intrahepatic cholangiocarcinoma after curative resection – A 13-year cohort in a tertiary center
  88. Impact of Hepatitis B Carrier Status on the Outcomes of Surgical Treatment of Colorectal Liver Metastases
  89. Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma
  90. Risk prediction model for major complication after hepatectomy for malignant tumour - A validated scoring system from a university center
  91. Laparoscopic liver resection versus percutaneous radiofrequency ablation in patients with hepatocellular carcinoma and liver cirrhosis: a case-matched study
  92. The role of oral antiviral therapy in hepatitis B-related hepatocellular carcinoma
  93. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma
  94. Oral Nucleos(t)ide Analogs Alone After Liver Transplantation in Chronic Hepatitis B With Preexisting rt204 Mutation
  95. Outcome of Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) vs Portal Vein Embolisation (PVE) for Hepatocellular Carcinoma
  96. Is Laparoscopic Major Hepatectomy Superior to Open Major Hepatectomy for Liver Cancer? A Matched Case-Control Study
  97. Comparable short- and long-term outcomes in deceased-donor and living-donor liver retransplantation
  98. Diagnostic and Prognostic Role of 18-FDG PET/CT in the Management of Resectable Biliary Tract Cancer
  99. Role of hepatic trisectionectomy in advanced hepatocellular carcinoma
  100. Secretory Stanniocalcin 1 promotes metastasis of hepatocellular carcinoma through activation of JNK signaling pathway
  101. Surgical strategy for huge and advanced hepatocellular carcinoma in Hong Kong
  102. Child-Pugh Parameters and Platelet Count as an Alternative to ICG Test for Assessing Liver Function for Major Hepatectomy
  103. Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: Results up to 8 years
  104. A new formula for estimation of standard liver volume using computed tomography-measured body thickness
  105. Efficacy of endoscopic self-expandable metal stent placement versus surgical bypass for inoperable pancreatic cancer-related malignant biliary obstruction: a propensity score-matched analysis
  106. Variation of stemness markers expression in tumor nodules from synchronous multi-focal hepatocellular carcinoma – an immunohistochemical study
  107. Hepatopancreatoduodenectomy for advanced hepatobiliary malignancies: a single-center experience
  108. Liver allograft biopsies with histological cholestasis: a clinicopathological study of 254 cases from a single centre
  109. Combined cavo-atrial thrombectomy and hepatectomy in hepatocellular carcinoma
  110. Acute hepatitis E virus infection causing acute liver failure requiring living-donor liver transplantation in a non-pregnant immunocompetent woman
  111. The role of radiofrequency ablation to liver transection surface in patients with close tumor margin of HCC during hepatectomy—a case matched study
  112. Updates on hepatorenal syndrome and strategies bridging to liver transplantation
  113. Late recurrence of hepatocellular carcinoma after liver transplantation
  114. Importance of Surgical Resection Margin in Colorectal Liver Metastases
  115. SENP1 promotes hypoxia-induced cancer stemness by HIF-1α deSUMOylation and SENP1/HIF-1α positive feedback loop
  116. Survival outcomes of hepatocellular carcinoma resection with postoperative complications – a propensity-score-matched analysis
  117. Liver transplantation: a life-saving procedure following amatoxin mushroom poisoning
  118. Lipid profiles of donors and recipients of liver transplant: like father like son
  119. Impact of split completeness on future liver remnant hypertrophy in associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) in hepatocellular carcinoma: Complete-ALPPS versus partial-ALPPS
  120. Resection of T4 hepatocellular carcinomas with adjacent structures, is it justified?
  121. Comparable Short- and Long-term Outcomes in Living Donor and Deceased Donor Liver Transplantations for Patients With Model for End-stage Liver Disease Scores ≥35 in a Hepatitis-B Endemic Area
  122. Importance of surgical margin in the outcomes of hepatocholangiocarcinoma
  123. Outcomes of right-lobe and left-lobe living-donor liver transplantations using small-for-size grafts
  124. No increase in graft fibrosis for hepatitis B surface antigen positive patients after liver transplantation using entecavir monotherapy
  125. Systematic review and meta-analysis of studies of biliary reconstruction in adult living donor liver transplantation
  126. An extra-adrenal pheochromocytoma mimicking a primary liver cancer
  127. Impact of intraoperative blood transfusion on long-term outcomes of liver transplantation for hepatocellular carcinoma
  128. Short- and long-term impact of reoperation for complications after major hepatectomy for hepatocellular carcinoma
  129. Serum and urinary biomarkers that predict hepatorenal syndrome in patients with advanced cirrhosis
  130. New insights after the first 1000 liver transplantations at The University of Hong Kong
  131. Pure Laparoscopic Hepatectomy Versus Open Hepatectomy for Hepatocellular Carcinoma in 110 Patients With Liver Cirrhosis
  132. Hepatobiliary and Pancreatic: Hepatic splenosis: a rare differential of a liver mass in an HBV endemic area
  133. The effect of wide resection margin in patients with intrahepatic cholangiocarcinoma
  134. Does hepatitis B seroconversion affect survival outcome in patients with hepatitis B related hepatocellular carcinoma?
  135. Simultaneous implantation of bilateral liver grafts in living donor liver transplantation with fusion venoplasty
  136. Biliary complications in right lobe living donor liver transplantation
  137. Prognostic influence of spontaneous tumor rupture on hepatocellular carcinoma after interval hepatectomy
  138. A detailed evaluation of cardiac function in cirrhotic patients and its alteration with or without liver transplantation
  139. Acute pancreatitis induced by transarterial chemoembolization: a single-center experience of over 1500 cases
  140. Excellent outcomes of liver transplantation using severely steatotic grafts from brain-dead donors
  141. Efficacy of radiofrequency ablation compared with transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma: a comparative survival analysis
  142. Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016
  143. Outcomes of endo-radiological approach to management of bile leakage after right lobe living donor liver transplantation
  144. Outcomes including liver histology after liver transplantation for chronic hepatitis B using oral antiviral therapy alone
  145. Durability of small-for-size living donor allografts
  146. Efficacy of radiofrequency ablation compared with transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma: a comparative survival analysis
  147. Pure Laparoscopic Versus Open Left Lateral Sectionectomy for Hepatocellular Carcinoma: A Single-Center Experience
  148. Liver Resection for De Novo Hepatocellular Carcinoma Complicated by Pyogenic Liver Abscess: A Clinical Challenge
  149. Clinical factors affecting rejection rates in liver transplantation
  150. Rare cause of jaundice in a post liver transplant patient
  151. Comparison of Survival Outcomes Between Right Posterior Sectionectomy and Right Hepatectomy for Hepatocellular Carcinoma in Cirrhotic Liver: A Single-Centre Experience
  152. The friendly incidental portal vein thrombus in liver transplantation
  153. Outcomes of hepatectomy for hepatocellular carcinoma with bile duct tumour thrombus
  154. Transplantation of a 2-year-old deceased-donor liver to a 61-year-old male recipient
  155. P0590 : Modified model for end stage liver disease score accurately predicts death or liver transplantation in acute flares of chronic hepatitis B
  156. Radiofrequency ablation versus transarterial chemoembolization for unresectable solitary hepatocellular carcinomas sized 5–8 cm
  157. Use of sorafenib in recurrent hepatocellular carcinoma (HCC) after liver transplantation.
  158. Resection of hepatocellular carcinoma after combined treatment with transarterial chemoembolization and sorafenib: a case report and literature review
  159. Management of recurrent hepatocellular carcinoma after liver transplant
  160. Combined sarcomatoid hepatocellular and cholangiocarcinoma: a case report and literature review
  161. Strategies to increase the resectability of hepatocellular carcinoma
  162. Prevention and management of biliary anastomotic stricture in right-lobe living-donor liver transplantation
  163. Retrospective study of metachronous lung metastases from primary hepatocellular carcinoma
  164. Good longterm survival after primary living donor liver transplantation for solitary hepatocellular carcinomas up to 8cm in diameter
  165. Correction: Management of Spontaneously Ruptured Hepatocellular Carcinomas in the Radiofrequency Ablation Era
  166. Defining an optimal surgical strategy for synchronous colorectal liver metastases: staged versus simultaneous resection?
  167. Pilot study of high-intensity focused ultrasound ablation as a bridging therapy for hepatocellular carcinoma patients wait-listed for liver transplantation
  168. Treatment Strategy to Improve Long-Term Survival for Hepatocellular Carcinoma Smaller than 5 cm: Major Hepatectomy vs Minor Hepatectomy
  169. Laparoscopic versus open liver resection for elderly patients with malignant liver tumors: A single-center experience
  170. Management of Spontaneously Ruptured Hepatocellular Carcinomas in the Radiofrequency Ablation Era
  171. Perpetuating proficiency in donor right hepatectomy for living donor liver transplantation
  172. A Retrospective Study on Risk Factors Associated With Failed Endoscopic Treatment of Biliary Anastomotic Stricture After Right-Lobe Living Donor Liver Transplantation With Duct-to-Duct Anastomosis
  173. Retransplantation using living-donor right-liver grafts
  174. Survival analysis of high-intensity focused ultrasound therapy vs. transarterial chemoembolization for unresectable hepatocellular carcinomas
  175. Samaritan donor interchange in living donor liver transplantation
  176. Technical Tips and Tricks for Living Donations
  177. Low-Volume Deceased Donor Liver Transplantation Alongside a Strong Living Donor Liver Transplantation Service
  178. Long Term Survival Analysis of Hepatectomy for Neuroendocrine Tumour Liver Metastases
  179. Pancreaticoduodenectomy with vascular reconstruction for adenocarcinoma of the pancreas with borderline resectability
  180. Feasibility of Laparoscopic Re-resection for Patients with Recurrent Hepatocellular Carcinoma
  181. Wait and Transplant for Stage 2 Hepatocellular Carcinoma With Deceased-Donor Liver Grafts
  182. Surgical Outcomes in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis
  183. Retrohepatic vena cava deroofing in living donor liver transplantation for caudate hepatocellular carcinoma
  184. Use of Liver Stiffness Measurement for Liver Resection Surgery: Correlation with Indocyanine Green Clearance Testing and Post-Operative Outcome
  185. Difference in cardiac manifestation between liver transplantation candidates with alcoholic and hepatitis related cirrhosis
  186. Survival analysis of high‐intensity focused ultrasound ablation in patients with small hepatocellular carcinoma
  187. Outcomes of central bisectionectomy for hepatocellular carcinoma
  188. Survival outcome of re-resection for recurrent liver metastases of colorectal cancer: a retrospective study
  189. Analysis of long-term survival after hepatectomy for isolated liver metastasis of gastrointestinal stromal tumour
  190. Survival outcomes of right-lobe living donor liver transplantation for patients with high Model for End-stage Liver Disease scores
  191. Evaluation of the seventh edition of the American Joint Committee on Cancer tumour–node–metastasis (TNM) staging system for patients undergoing curative resection of hepatocellular carcinoma: implications for the development of a refined staging system
  192. Oral Nucleoside/Nucleotide Analogs Without Hepatitis B Immune Globulin After Liver Transplantation for Hepatitis B
  193. Improvising hepatic venous outflow and inferior vena cava reconstruction for combined heart and liver and sequential liver transplantations
  194. Survival Analysis of High-Intensity Focused Ultrasound Therapy Versus Radiofrequency Ablation in the Treatment of Recurrent Hepatocellular Carcinoma
  195. Treatment strategy for recurrent hepatocellular carcinoma: Salvage transplantation, repeated resection, or radiofrequency ablation?
  196. Long-Term Survival Analysis of Pure Laparoscopic Versus Open Hepatectomy for Hepatocellular Carcinoma in Patients With Cirrhosis
  197. Outcomes of side-to-side conversion hepaticojejunostomy for biliary anastomotic stricture after right-liver living donor liver transplantation
  198. 11C-Acetate and 18F-FDG PET/CT for Clinical Staging and Selection of Patients with Hepatocellular Carcinoma for Liver Transplantation on the Basis of Milan Criteria: Surgeon's Perspective
  199. Rescue Living-donor Liver Transplantation for Liver Failure Following Hepatectomy for Hepatocellular Carcinoma
  200. High-intensity focused ultrasound ablation: An effective bridging therapy for hepatocellular carcinoma patients
  201. Radiological prognosticators of hepatocellular carcinoma treated by hepatectomy
  202. Remnant left liver size and recovery of living right liver donors
  203. Recurrence of hepatocellular cancer after liver transplantation: The role of primary resection and salvage transplantation in East and West
  204. Evaluation of Survival after Primary Liver Transplantation for Hepatocellular Carcinoma Within UCSF Criteria
  205. Increasing the Recipient-Benefit to Donor-Risk Ratio by Lowering the Graft Size Requirement for Living Donor Liver Transplantation
  206. Outcome of laparoscopic versus open hepatectomy for colorectal liver metastases
  207. High-intensity focused ultrasound ablation as a bridging therapy for hepatocellular carcinoma patients awaiting liver transplantation
  208. Effects of donor steatosis on liver biochemistry and significance of body mass index in predicting steatosis
  209. Increasing the recipient benefit/donor risk ratio by lowering the graft size requirement for living donor liver transplantation
  210. Bile duct anastomotic stricture after pediatric living donor liver transplantation
  211. Outcomes of living donor liver transplantation for patients with preoperative type 1 hepatorenal syndrome and acute hepatic decompensation
  212. Tolerance of High-Intensity Focused Ultrasound Ablation in Patients with Hepatocellular Carcinoma
  213. Rapid measurement of indocyanine green retention by pulse spectrophotometry: a validation study in 70 patients with Child-Pugh A cirrhosis before hepatectomy for hepatocellular carcinoma
  214. The impact of family history of hepatocellular carcinoma on its patients' survival
  215. 147 HCC RECURRENCE AFTER LIVER TRANSPLANTATION IN ASIA VS. EUROPE: WHICH IS THE DIFFERENCE?
  216. Single-centre experience of liver transplantation for familial amyloidotic polyneuropathy of non-Val30Met variants in Chinese patients
  217. Re-resection for metachronous primary hepatocellular carcinoma: is it justified?
  218. Modulation of graft vascular inflow guided by flowmetry and manometry in liver transplantation
  219. Effects of the liver volume and donor steatosis on errors in the estimated standard liver volume
  220. Survival Analysis of Re-resection Versus Radiofrequency Ablation for Intrahepatic Recurrence After Hepatectomy for Hepatocellular Carcinoma
  221. Survival advantage of primary liver transplantation for hepatocellular carcinoma within the up-to-7 criteria with microvascular invasion
  222. Entecavir Monotherapy Is Effective in Suppressing Hepatitis B Virus After Liver Transplantation
  223. Can positron emission tomography with the dual tracers [11C]acetate and [18F]fludeoxyglucose predict microvascular invasion in hepatocellular carcinoma?
  224. Emergency re-routing of anterior sector venous outflow for right lobe living donor liver transplantation including the middle hepatic vein
  225. Impact of Antiviral Therapy on the Survival of Patients After Major Hepatectomy for Hepatitis B Virus–Related Hepatocellular Carcinoma
  226. Late Recurrence of Hepatocellular Carcinoma after Liver Transplantation
  227. High-Intensity Focused Ultrasound for Hepatocellular Carcinoma
  228. Validation of graft and standard liver size predictions in right liver living donor liver transplantation
  229. Bile duct anastomotic stricture after adult-to-adult right lobe living donor liver transplantation
  230. Results of percutaneous transhepatic cholecystostomy for high surgical risk patients with acute cholecystitis
  231. Combined resection and radiofrequency ablation for multifocal hepatocellular carcinoma: Prognosis and outcomes
  232. The outcomes of elderly patients with hepatocellular carcinoma treated with transarterial chemoembolization
  233. Radiofrequency ablation for controlling iatrogenic splenic injury
  234. Simplifying hepatic venous outflow reconstruction in sequential living donor liver transplantation
  235. Liver transplantation for hepatocellular carcinoma: the Hong Kong experience
  236. An Update on Long-Term Outcome of Curative Hepatic Resection for Hepatocholangiocarcinoma
  237. Impact of postoperative complications on long-term outcome of curative resection for hepatocellular carcinoma
  238. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population
  239. Safety and Efficacy of Radiofrequency Ablation for Periductal Hepatocellular Carcinoma with Intraductal Cooling of the Central Bile Duct
  240. Risk Factors and Prognostic Factors of Local Recurrence after Radiofrequency Ablation of Hepatocellular Carcinoma
  241. Efficacy and tolerability of single agent sorafenib in poor risk advanced hepatocellular carcinoma patients
  242. Incomplete Ablation After Radiofrequency Ablation of Hepatocellular Carcinoma: Analysis of Risk Factors and Prognostic Factors
  243. Long-term survival after resection of extrahepatic recurrence of hepatocellular carcinoma at the right colon
  244. FACTORS AFFECTING FALSE-NEGATIVE BREAST SENTINEL NODE BIOPSY IN CHINESE PATIENTS
  245. Prognostic Factors Affecting Survival and Recurrence of Patients with pT1 and pT2 Colorectal Cancer
  246. Obscure traumatic cardiac lesion after a penetrating chest injury: Review of the literature
  247. Efficacy and Tolerability of Low-Dose Thalidomide as First-Line Systemic Treatment of Patients with Advanced Hepatocellular Carcinoma
  248. Comparable Survival in Patients With Unresectable Hepatocellular Carcinoma Treated by Radiofrequency Ablation or Transarterial Chemoembolization
  249. Prospective Randomized Trial on Low-pressure Versus Standard-pressure Pneumoperitoneum in Outpatient Laparoscopic Cholecystectomy
  250. Five-year experience of outpatient laparoscopic cholecystectomy in Hong Kong.
  251. Selective Portal Vein Clamping for Radiofrequency Ablation of Hepatocellular Carcinoma With Portal Vein Invasion
  252. Outpatient Laparoscopic Cholecystectomy in Hong Kong Chinese – An Outcome Analysis
  253. Management of hepatocellular carcinoma in renal transplant recipients
  254. Management of biliary anastomotic stricture in living-donor liver transplantation